{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:27:30Z","timestamp":1776259650753,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T01:25:44Z","timestamp":1642901144000},"page":"S30-S37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation"],"prefix":"10.1016","volume":"135","author":[{"given":"Maya","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.amjmed.2022.01.011_bib0001","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.011_bib0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.amjmed.2022.01.011_bib0003","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.amjmed.2022.01.011_bib0004","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.011_bib0009","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","article-title":"Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis","volume":"35","author":"Szalat","year":"2021","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.amjmed.2022.01.011_bib0010","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant research study","volume":"33","author":"D'Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.011_bib0011","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.011_bib0012","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjh.16143","article-title":"A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom","volume":"187","author":"Sharpley","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.011_bib0013","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.011_bib0014","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.amjmed.2022.01.011_bib0015","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.amjmed.2022.01.011_bib0016","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.011_bib0017","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.011_bib0018","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2016.05.027","article-title":"The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation","volume":"22","author":"Dittus","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.011_bib0005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.011_bib0019","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.amjmed.2022.01.011_bib0006","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.011_bib0008","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.amjmed.2022.01.011_bib0021","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.011_bib0022","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.011_bib0023","unstructured":"National Institutes of Health, U.S. National Library of Medicine, ClinicalTrials.gov. A study to evaluate the efficacy and safety of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to CyBorD alone in newly diagnosed systemic amyloid light-chain (AL) amyloidosis [study results]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03201965. Accessed April 24, 2021."},{"key":"10.1016\/j.amjmed.2022.01.011_bib0024a","doi-asserted-by":"crossref","unstructured":"Kastritis E, Palladini G, Minnema MC, et al.; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021;385(1):46-58","DOI":"10.1056\/NEJMoa2028631"},{"key":"10.1016\/j.amjmed.2022.01.011_bib0007","unstructured":"Comenzo R, Kastritis E, Palladini G, et al. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from Andromeda. Available at: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper137582.html. Accessed April 24, 2021."},{"key":"10.1016\/j.amjmed.2022.01.011_bib0024","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants accelerated approval to Darzalex Faspro for newly diagnosed light chain amyloidosis. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis. Accessed April 27, 2021."},{"issue":"16","key":"10.1016\/j.amjmed.2022.01.011_bib0025","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","article-title":"Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis","volume":"124","author":"Reece","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.011_bib0026","doi-asserted-by":"crossref","first-page":":225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis(RRAL)","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.amjmed.2022.01.011_bib0028","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.amjmed.2022.01.011_bib0029","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.amjmed.2022.01.011_bib0030","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a Phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.011_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.011_bib0032","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.1002\/ajh.25497","article-title":"Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: a pooled analysis","volume":"94","author":"Sanchorawala","year":"2019","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.amjmed.2022.01.011_bib0033","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2020005436","article-title":"AL patients don't dare go without dara","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.011_bib0034","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.amjmed.2022.01.011_bib0035","unstructured":"U.S. Food and Drug Administration (FDA). FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. Available at: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia. Accessed April 25, 2021."},{"key":"10.1016\/j.amjmed.2022.01.011_bib0036","unstructured":"U.S. Food and Drug Administration (FDA). FDA approves venetoclax for CLL and SLL. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll. Accessed April 25, 2021."},{"key":"10.1016\/j.amjmed.2022.01.011_bib0037","unstructured":"Kastritis E, Palladini G, Minnema MC, et al. ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:25:38Z","timestamp":1757582738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":36,"alternative-id":["S0002934322000316"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.011","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}